Nano-X Imaging Ltd. (NASDAQ: NNOX), a company focused on transforming medical imaging through an integrated healthcare platform, has entered into a securities purchase agreement with a single long-term institutional investor. The registered direct offering is expected to generate approximately $8 million in gross proceeds before fees and expenses.
The financing involves the sale of 8 million ordinary shares, or prefunded warrants in lieu thereof, accompanied by warrants to purchase up to an additional 8 million ordinary shares. The combined purchase price is $1.00 per share and accompanying warrant. The warrants carry an exercise price of $1.15 per share, become exercisable six months after issuance, and expire five years after closing.
The offering is anticipated to close on or about August 7, 2026, subject to customary closing conditions. Nano-X stated that it intends to use the net proceeds for working capital and general corporate purposes. A.G.P./Alliance Global Partners is serving as the sole placement agent for the transaction.
This capital raise comes as Nano-X continues to advance its mission of driving the world’s transition to preventive healthcare. The company’s platform integrates affordable imaging hardware, AI-based solutions, cloud-based software, remote radiology access, health IT solutions, and a marketplace, aiming to enable earlier detection and broader access to care.
Key components of the Nanox ecosystem include the Nanox.ARC, a 3D multi-source digital tomosynthesis system; Nanox.AI, which augments CT imaging interpretation; Nanox.CLOUD for secure data management; Nanox.MARKETPLACE and USARAD Holdings for teleradiology services; and Nanox Health IT, which provides RIS, PACS, AI, and dictation solutions. By integrating these technologies, Nanox seeks to lower barriers to adoption and improve utilization of medical imaging.
The funding will support the company’s ongoing operations as it works to expand its reach beyond traditional hospital settings, offering a seamless solution from scan to interpretation. The company’s vision is to enhance routine imaging workflows and support early disease detection, potentially improving patient outcomes.
Investors and industry observers will be watching how Nano-X utilizes these funds to progress its commercial rollout and further develop its platform. The offering’s completion, expected in August 2026, will provide additional capital to support the company’s strategic initiatives.
For more details on the offering, the full press release is available at this link. Information about Nano-X and its technologies can be found on their official website.
The announcement underscores Nano-X’s continued efforts to secure funding for its growth plans in the competitive medical imaging sector.
